News and features

Articles

Showing 1 - 10 of 15

News & Analysis

New Measures on Syndicated Loans: Policy Shifts and Insights

25 October 2024 by Han Kun Law Offices

The National Financial Regulatory Administration (“NFRA”) issued the Administrative Measures for Syndicated Loan Business (“Administrative Measures”) on 12 October 2024, which will take effect from 1 November 2024 and shall amend and replace the Guidelines on Syndicated Loan Business issued by the China Banking Regulatory Commission on 1 August 2011 (the “Business Guidelines”).

News & Analysis

China Pilots Lifting Restrictions on Foreign Investment in Stem Cell, Gene Therapy, and Genetic Diagnosis Sectors in Four Free Trade Zones

11 September 2024 by Han Kun Law Offices - China

On September 8, 2024, the Ministry of Commerce, together with the National Health Commission and the National Medical Products Administration publicly issued the Notice on Carrying Out Pilot Programs to Expand Opening-Up in the Healthcare Sector

News & Analysis

Han Kun Releases Its 2023 VC/PE Data Analysis Report

30 July 2024 by Han Kun Law Offices

Onshore Transactions Continued their Upward Trend while VIE Structure Lost Luster for Offshore Transactions

News & Analysis

Han Kun advises on JD.com, Inc.'s US$ 2.0 billion convertible senior notes offering

29 May 2024 by Han Kun Law Offices

Han Kun advises on JD.com, Inc.'s US$ 2.0 billion convertible senior notes offering

News & Analysis

Han Kun provides data compliance counsel to Lucas GC's listing on Nasdaq

06 March 2024 by Han Kun Law Offices

Han Kun provides data compliance counsel to Lucas GC's listing on Nasdaq

News & Analysis

First Insights into China’s New Corporate Landscape

05 January 2024 by Ray SHI, Claire XU

Barely a week ago on December 29, 2023, China’s legislative body passed and President Xi Jinping signed into law the newly revised Company Law, effective from July 1, 2024 (the “New Law”).

News & Analysis

Anatomy of Licensing Deals from China Regulatory Perspective

04 January 2024 by Aaron GU, Pengfei YOU, Duzhiyun ZHENG, Yuzhen ZHANG, Fengqi YU

Driven by the passion and belief, and fraught with various risks and challenges, the research and development of innovative drugs and medical devices is a journey that’s never easy.

News & Analysis

ESG Banking Products in China — (I) Green Deposits

03 January 2024 by Ting ZHENG, Raymond YAN, Eryin YING, Lin ZHU

ESG is in high alignment with China’s “dual carbon” goals and has become an important indicator for measuring the sustainable and high-quality development of enterprises in China

News & Analysis

Han Kun Releases Its 2022 VC/PE Data Analysis Report

18 September 2023 by Han Kun Law Offices - China

Onshore Transactions Continued their Upward Trend, the Biomedical Sector Remained the Most Popular Investment Destination

News & Analysis

Han Kun Releases 2021 Fund Practice Data Analysis Report: PE fund market rebounded. Smart hardware and biomedicine retained the crown

02 December 2022 by Han Kun Law Offices - China

In 2021, markets appeared to reach a new equilibrium following the widespread rampage wrought by Covid-19 the year before, as many economies gradually adjusted to the “new normal” and business activities saw a sharp rebound.